YiMufeng's Next-Gen SNR-CAR-T Therapy IMC008 Receives FDA Orphan Drug Designation for Gastric Cancer
Immunofoco
Developer of Novel Therapeutics for Solid Tumors
FDA
U.S. Food and Drug Administration
On August 16, Immunofoco announced that its self-developed next-generation autologous CAR-T product IMC008, based on the company's SNR technology platform, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer patients.
Immunofoco's self-developed SNR technology platform is specifically designed to overcome tumor heterogeneity, contributing to a breakthrough in solid tumor treatment. The Orphan Drug Designation highlights the significant potential of IMC008 in the field of gastric cancer treatment, offering new hope for patients with gastric cancer.
IMC008 is a next-generation autologous CAR-T product developed based on the Synthetic Natural Killer Receptor (SNR) technology platform. Tumor antigen heterogeneity has always been one of the key factors limiting the therapeutic efficacy of CAR-T in solid tumors. The SNR platform, through dual recognition and functional enhancement mechanisms, not only targets specific antigens but also broadens the antigen recognition range of CAR-T cells via SNR receptors, effectively addressing the challenges posed by tumor antigen heterogeneity. Additionally, the SNR signal synergizes with the CAR signal, further enhancing the proportion of memory T cells in CAR-T cells, improving their expansion and tumor infiltration in animal models, and strengthening their ability to eliminate antigen-heterogeneous tumor tissues.
IMC008 Receives Orphan Drug Designation: A Significant Milestone for Immunofoco in Advancing Innovations to Tackle Solid Tumors
Editor: Mu Mian
Disclaimer: This article is a reprint from Yaozhi.com. The images and text are the original property of the author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.
